GHRP-6 Research: What 687 Studies Show (2026) | RetatrutideCompare

GHRP-6 — 687 studies indexed on PubMed. First-generation synthetic ghrelin receptor agonist with strong appetite-stimulating effect via NPY/AgRP neurons. Half-life: ~30 minutes. FDA status: Not FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on GHRP-6?

There are approximately 687 studies indexed on PubMed that mention GHRP-6 (Growth Hormone Releasing Peptide-6), based on a search last updated 2026-06-18.

Is GHRP-6 FDA-approved?

FDA status: Not FDA-approved.

How does GHRP-6 work?

First-generation synthetic ghrelin receptor agonist with strong appetite-stimulating effect via NPY/AgRP neurons.

First-generation synthetic ghrelin receptor agonist with strong appetite-stimulating effect via NPY/AgRP neurons.

Reference facts

Also known as
Growth Hormone Releasing Peptide-6
Category
Growth Hormone & Ghrelin
Mechanism of action
First-generation synthetic ghrelin receptor agonist with strong appetite-stimulating effect via NPY/AgRP neurons.
Targets
GHS-R1a
Indications under research or approved
Research (cachexia, GH testing)
Regulatory status (reference entry)
Not FDA-approved
Half-life
~30 minutes
Sequence notes
Hexapeptide H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2.
Molecular weight (Da)
873
First reported
1980

Primary References

Explore research articles about GHRP-6

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.